{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Pulmonx Corp. technically bullish or bearish?
As of June 11, 2025, the technical trend has shifted to a bearish stance, indicated by a bearish MACD, Bollinger Bands, and moving averages, along with underperformance against the S&P 500.
Who are in the management team of Pulmonx Corp.?
As of March 2022, the management team of Pulmonx Corp. includes Chairman Dana Mead, President and CEO Glendon French, and Directors Thomas Burns and Georgia Garinois-Melenikiotou.
What does Pulmonx Corp. do?
Pulmonx Corporation is a medical technology company specializing in treatments for obstructive lung disease, with recent net sales of $23 million and a net loss of $14 million. It has a market cap of $109.10 million and key metrics indicating it is currently loss-making.
How big is Pulmonx Corp.?
As of Jun 18, Pulmonx Corp. has a market capitalization of 109.10 million, with net sales of 87.48 million and a net profit of -57.10 million over the last four quarters. Shareholder's funds are reported at 85.81 million, and total assets amount to 167.71 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
